TrumpRx, the federal direct-to-consumer drug discount website President Donald Trump launched Feb. 5, reaches its six-month mark Aug. 5. The site has grown from 40 branded drugs at launch to 92 in July, with more than 600 generics added in May. But that catalog still covers fewer than 12% of the more than 800 brand-name drugs made by the 17 manufacturers that signed most-favored-nation pricing deals with the administration, according to an NPR analysis of an FDA drug database published July 16.
Measured against its own launch promise of a marketplace for cheaper drugs, TrumpRx’s six-month record is a mixed verdict. Below is what the site has and hasn’t delivered on each of the questions that mattered most at launch.
Delivered: real discounts on a narrow list of drugs
TrumpRx is cash-pay only. It does not process payments or dispense drugs, instead routing patients to manufacturer coupons and portals through partners including GoodRx, Cost Plus Drugs and, since May, Amazon Pharmacy. Within that structure, the discounts themselves are real. At launch, GLP-1 prices fell as much as 85% through the site and fertility drugs saw average savings of more than $2,000 a treatment cycle. Many of the 600-plus generics added in May are priced under $5.
What TrumpRx has not delivered is breadth. Pfizer has the largest footprint on the site with 30 listed drugs, but that’s just a fraction of its 178 brand-name products on the market, and revenue drivers, including Eliquis, Ibrance and Paxlovid are absent, according to NPR. Gilead and Regeneron signed MFN agreements months ago but still have no drugs live on the site, though both companies told NPR they plan to add one each: Gilead’s Epclusa and Regeneron’s Praluent, without a firm timeline. Overall, the 17 participating manufacturers have listed less than 12% of their combined brand-name portfolios.
Not delivered: the “lowest price” promise
The administration’s pitch was that TrumpRx would carry the lowest available price on each listed drug. Six months in, that claim doesn’t hold up consistently. Novo Nordisk lists Ozempic at $350 a month on TrumpRx, above the roughly 40% average discount many patients already get through Medicare Part D and well above Medicaid’s discounts of more than 75%. A March review of the site found German public system prices were lower in more than half of comparisons, sometimes by thousands of dollars a month for patent-protected drugs. NPR found the same pattern holds for some generics: Merck’s Janumet undercuts the generic version sold on Cost Plus Drugs, while Pfizer’s Pristiq lists on TrumpRx for $200.10, even though its generic runs $20 to $30 with a GoodRx coupon.
Not delivered, yet: broad adoption
A marketplace only works if patients use it. About one-third of patients report knowing TrumpRx exists and 7% say they have used it to compare prices, a figure that rises to 16% among GLP-1 users. The administration’s bet for closing that gap is distribution rather than pricing. Amazon Pharmacy is on track to reach same-day prescription delivery in 4,500 cities by the end of 2026, a partnership TrumpRx added in May alongside its generics expansion. If that rollout proceeds on schedule, it could move the awareness numbers. It does not, on its own, close the catalog gap on branded drugs that NPR identified.
Still pending: whether the model outlasts this administration
TrumpRx’s durability rests on decisions the site itself doesn’t control. President Trump’s Jan. 15 healthcare proposal calls on Congress to codify most-favored-nation pricing, and CMS Administrator Mehmet Oz, MD, has said he expects 95% of U.S. drugs to carry MFN pricing by the end of the term, a target the current pace of new listings hasn’t kept up with. Several manufacturers also tied their MFN commitments to U.S. investment pledges rather than broad price cuts. Pfizer pledged $70 billion to $90 billion and AstraZeneca $50 billion in domestic manufacturing and research in exchange for tariff relief, a trade-off health policy researchers told NPR helps explain why participation has stayed concentrated in a limited set of products.
The model also bypasses pharmacy benefit managers entirely, sending patients straight to manufacturer cash prices instead of through formularies or benefit design, which is drawing scrutiny alongside a separate ethics question raised by financial disclosures showing President Trump’s personal accounts purchased Eli Lilly stock as his administration advanced Medicare coverage for GLP-1 drugs, including the Medicare GLP-1 Bridge program that took effect this month.
The verdict on who it’s actually reaching
Health policy researchers told NPR that TrumpRx is most useful for uninsured and underinsured cash-paying patients, particularly those seeking fertility treatment or obesity medications that insurance frequently excludes. That is not the majority of prescription drug users. Insured patients are often better off checking their copay first, a caveat TrumpRx displays on the site.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
